Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis

作者：Fragoso Yara Dadalti; Adoni Tarso; Alves Leon Soniza Vieira; Apostolos Pereira Samira Luisa; de Araujo Yuna Ribeiro; Becker Jefferson; Bidin Brooks Joseph Bruno; Correa Eber Castro; Damasceno Alfredo; de Albuquerque Damasceno Carlos Augusto; Ferreira Maria Lucia B; da Gama Paulo Diniz; Diniz da Gama Rodrigo Assad; Gomes Sidney; Magno Goncalves Marcus Vinicius; Grzesiuk Anderson Kuntz; Nunes Machado Suzana Costa; da Cunha Matta Andre Palma; Mendes Maria Fernanda

来源：Expert Review of Clinical Pharmacology, 2016, 9(4): 541-546.

DOI：10.1586/17512433.2016.1145053

• fingolimod
• Natalizumab
• progressive multifocal leukoencephalopathy
• multiple sclerosis

Natalizumab is a therapeutic option for treating multiple sclerosis (MS) and is particularly efficacious for patients with highly active disease. A long washout period has been recommended between withdrawal of natalizumab and start of fingolimod (another option for treating MS). This long washout period has been associated with a significant increase in MS activity. In the present study, a group of 96 patients who were switched from natalizumab to fingolimod had short washout periods between drugs, or monthly corticosteroid pulse therapy if longer washout periods were recommended. This therapeutic approach led to the lowest reported relapse rate so far, among patients with MS switching from natalizumab to fingolimod (8.3%). No complications from short withdrawal were observed in this group of patients.

• 出版日期2016-4-2